Safety of Insulin Glargine in PregnancySameer Ansar, Saadia Mian, Steven Roth, George Matthew Hebdon, Saleh Aldasouqi and Ved V Gossain*
Endocrinology Fellowship, College of Human Medicine, USA
- *Corresponding Author:
- Ved V Gossain
Program Director, Endocrinology Fellowship
College of Human Medicine, Clinical Center Building
788 Service Road, Room B323, East Lansing
MI 48824-7016, USA
Tel: (517) 353-3730
Fax: (517) 432-1326
E-mail: [email protected]
Received date: November 01, 2012; Accepted date: December 26, 2012; Published date: December 29, 2012
Citation: Ansar S, Mian S, Roth S, Hebdon GM, Aldasouqi S, et al. (2013) Safety of Insulin Glargine in Pregnancy. J Diabetes Metab 4:240. doi:10.4172/2155-6156.1000240
Copyright: © 2013 Ansar S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aim: Although insulin glargine is frequently being used in pregnancy, it is not approved by the FDA as the data on its safety is limited. The aim of this study was to determine the effects of insulin glargine use in pregnancy on maternal and fetal outcomes.
Methods: From the perinatal center at Sparrow Hospital, Lansing, Michigan the charts of 92 women with diabetes (gestational diabetes, type 1 diabetes and type 2 diabetes) who were treated with insulin glargine during pregnancy were reviewed. Maternal and fetal outcomes were recorded.
Results: Eighteen women had continued pre-pregnancy insulin glargine use through pregnancy and 74 were started on insulin glargine during pregnancy. The average HbA1c was 7.7%, 7.1% and 6.3% respectively in 1st, 2nd, and 3rd trimester. 31% of the woman had hypoglycemic episodes. No maternal deaths were reported. One pregnancy resulted in intrauterine fetal death. The rate of cesarean sections was 45% and the average age of gestation at delivery was 36 weeks. 12% of the newborns had macrosomia (defined as birth weight >4000 pounds), 2% had shoulder dystocia, and 7% had neonatal hypoglycemia. The data were compared to the outcome from prior studies of pregnant patients in NPH and insulin glargine.
Conclusion: We present data on maternal and perinatal outcomes with use of insulin glargine during pregnancy at our institution. Our data compares favorably with the outcome from other studies of pregnant patients using NPH insulin.